Combined immunotherapy with anti-PD-1/PD-L1 and anti-CTLA4 has resulted in superior clinical responses compared to single agent therapy. The underlying mechanisms for this synergy have yet to be elucidated and investigations have largely focused on cellular interactions. Herein, we report a molecular crosstalk in which the PD-1 ligand PD-L1 and the CTLA4 ligand CD80 heterodimerize in cis. This heterodimerization blocks both PD-L1:PD-1 and CD80:CTLA4 interactions, but preserves the ability of CD80 to activate the T cell costimulatory receptor CD28. Remarkably, PD-L1 expression on antigen presenting cells (APCs) protects CD80 from CTLA4 mediated trans-endocytosis, and the therapeutic PD-L1 blockade antibody atezolizumab paradoxically downregulates CD80 on APCs, presumably reducing its co-stimulatory ability. Importantly, this effect can be negated by co-blockade of CTLA4 with ipilimumab. Our study reveals an unexpected immune stimulatory role of cis-acting PD-L1 and a mechanism of anti-PD-L1/anti-CTLA4 crosstalk, providing a therapeutic rationale for combination blockade of PD-L1 and CTLA4.
INTRODUCTION
Programmed cell death-1 (PD-1) and cytotoxic T lymphocyte-associated protein-4 (CTLA4) are two central co-inhibitory receptors that restrict T cell activity (Nishimura et al., 1999; Tivol et al., 1995; Waterhouse et al., 1995) . Antibodies that block CTLA4 or PD-1/PD-L1 pathways have demonstrated impressive clinical activities against an array of human cancers in a subset of patients (Hodi et al., 2010; Powles et al., 2014; Ribas and Wolchok, 2018; Rizvi et al., 2015; Topalian et al., 2012) . Notably, the combination of anti-CTLA4 and anti-PD-1 has proven more effective than either agent alone and recently approved by the FDA for treatment of human melanoma and renal cancer patients (Callahan et al., 2014; Larkin et al., 2015; Wei et al., 2018) . Nevertheless, durable response to this combination therapy is restricted to a minority of patients and cancer indications . Therefore, a better mechanistic understanding of anti-PD-1/PD-L1, anti-CTLA4, and their crosstalk, is needed for rational design of combination therapies.
Binding of T-cell-intrinsic PD-1 with its ligand PD-L1 (Dong et al., 1999; Freeman et al., 2000) on APCs triggers tyrosine phosphorylation of PD-1 and recruitment of SHP2, a phosphatase that dephosphorylates T cell receptor (TCR) and CD28 costimulatory signaling components (Hui et al., 2017; Parry et al., 2005; Sheppard et al., 2004; Yokosuka et al., 2012) . CTLA4 outcompetes CD28 for their shared ligands, CD80 and CD86, due to its substantially higher affinities to both ligands (Krummel and Allison, 1995; Linsley et al., 1991; van der Merwe et al., 1997) . Additionally, CTLA4 depletes CD80 and CD86 molecules from APCs via trans-endocytosis to indirectly inhibit CD28 signaling (Qureshi et al., 2011; Wing et al., 2008) . Intriguingly, PD-L1 and CD80 were reported to bind each other, suggesting another layer of crosstalk among PD-1, CTLA4 and CD28 pathways. However, the biochemical nature and cell biology consequence of PD-L1:CD80 interaction remain elusive. The original reports suggest that PD-L1 and CD80 bind in trans from different cells (Butte et al., 2007; Butte et al., 2008) , yet recent studies suggest that they interact in cis on the same cells (Chaudhri et al., 2018) . Dissecting the function of PD-L1:CD80 interaction is challenging due to a complex network consisting of two ligands (PD-L1 and CD80) and three receptors (PD-1, CD28 and CTLA4). Here we employed in vitro reconstitution and engineered cell lines to decouple and dissect the fiveprotein signaling network. We elucidated the functional consequences of PD-L1:CD80 interaction and uncovered an unexpected crosstalk among CD28, PD-1 and CTLA4 pathways at the extracellular level.
RESULTS

PD-L1 and CD80 interact only in cis
We first asked whether PD-L1 binds to CD80 in trans from different membranes. To this end, we utilized a membrane adhesion assay , in which transinteraction between two proteins is measured as the association of two model membranes: large unilamellar vesicles (LUVs) and a supported lipid bilayer (SLB).
Specifically, we reconstituted His-tagged ectodomains of PD-L1 (PD-L1-His) and its binding partner, CD80 or PD-1, to Bodipy-PE containing LUVs and an SLB, respectively, via the chelating lipid DGS-NTA-Ni. Incubation of PD-L1 LUVs with the PD-1 SLB led to a number of SLB-associated LUVs, as visualized by total internal reflection fluorescence (TIRF) microscopy. By contrast, CD80-SLB captured 99% fewer PD-1 LUVs, similar to SLB with SLB with CD86, a negative control with no reported PD-L1 binding activity ( Figure 1A) . Hence, PD-L1 does not bind CD80 in trans, consistent with a recent study (Chaudhri et al., 2018) .
We next determined whether PD-L1 and CD80 bind in cis using a Förster resonance energy transfer (FRET) in a HEK293T cell reconstitution system . To this end, we co-transfected HEK293T cells with CLIP-tagged PD-L1 and SNAP-tagged CD80, and labeled them with Dy547 (energy donor) and Alexa Fluor 647 (AF647, energy acceptor) respectively. Photo-bleaching of AF647-CD80 substantially increased the fluorescence of Dy547-PD-L1 ( Figure 1B, upper) , indicative of FRET. Replacement of CD80 with CD86 ( Figure 1B, lower) , or PD-L1 with PD-L2 dramatically decreased the FRET signal ( Figure 1C ). These data suggest that PD-L1 associates with CD80 in cis on cell membranes. We next examined this cis-interaction quantitatively in an LUV reconstitution assay. Specifically, we attached DGS-NTA-Ni containing LUVs with purified PD-L1-His labeled with energy donor ]. Subsequent addition of energy acceptor [tetramethyl rhodamine (TMR)] labeled CD80-His, but not CD80 lacking the membrane-targeting His-tag, quenched PD-L1 fluorescence ( Figure 1D , black versus purple). This result indicates that PD-L1:CD80 cis-interaction on membranes has a much higher affinity than their interaction in solution (Cheng et al., 2013) . CD80-His also induced a reproducible, but much weaker quenching of LUV-bound PD-L2 ( Figure 1D , yellow), owing to a molecular crowding effect. Importantly, atezolizumab, a PD-L1
antibody that blocks both PD-L1:PD-1 interaction and PD-L1:CD80 interaction (Herbst et al., 2014) , decreased the PD-L1:CD80 FRET to a similar level as PD-L2:CD80 FRET ( Figure 1D, blue) . These results demonstrate that PD-L1 and CD80 bind directly in cis and that this cis-interaction can be blocked by atezolizumab.
PD-L1:CD80 cis-interaction blocks PD-L1:PD-1 signaling
Having established that CD80 binds PD-L1 in cis, we next sought to determine if CD80 inhibits PD-L1:PD-1 interaction. PD-1-Fc stained PD-L1 transduced, CD80 knockout Raji (PD-L1+/CD80 KO) B cells in a concentration dependent manner (Figure 2A, red) . Coexpression of CD80 (3.5-fold excess of PD-L1) dramatically decreased PD-1-Fc staining (Figure 2A , blue, see Figure S1 for quantitation of PD-L1 and CD80 levels), indicating that PD-L1:CD80 cis-interaction inhibits PD-L1:PD-1 interaction. To extend the analysis to membrane-bound PD-1, we then employed a T cell-lipid bilayer hybrid system in which a cytotoxic T cell interacts with a SLB functionalized with peptide-linked-majorhistocompatibility-complex (pMHC) and PD-L1. As reported (Hui et al., 2017; Yokosuka et al., 2012; Zhao et al., 2018) , interaction of PD-1 on T cells with PD-L1 on SLB in trans led to the formation of PD-1 microclusters. Strikingly, addition of CD80-His (three-fold excess to PD-L1) to the PD-L1/pMHC SLB completely abolished PD-1 microclusters ( Figure 2B ). By contrast, equivalent levels of CD86-His did not affect PD-1 clustering ( Figure 2B ). TCR microclusters remained intact under all conditions ( Figure S2) . Thus, CD80 selectively inhibits PD-L1:PD-1 interaction.
We next extended our investigation to a T cell-APC co-culture system consisting of PD-1-mGFP transduced Jurkat T cells and PD-L1-mCherry transduced Raji APCs (Tian et al., 2015) . We created three Raji lines expressing similar levels of PD-L1-mCherry (~1700 molecules per μm 2 ) but increasing levels of CD80: PD-L1+/CD80 KO), PD-L1+/CD80 low (~600 CD80 molecules per μm 2 ), and PD-L1+/CD80 high (~6000 CD80 molecules per μm 2 ) ( Figure 2C & D, Figure S1 ). Notably, these cells express PD-L1 and CD80 at comparable levels with those on human monocytes derived dendritic cells (DCs) ( Figure   S3 ). Conjugation of superantigen SEE-loaded Raji (PD-L1+/CD80 KO) cells with Jurkat (PD-1+) cells enriched both PD-L1 and PD-1 to their interface. The CD80 low Raji cells, which express 2.9-fold lower CD80 than PD-L1 ( Figure S1 ), had little effect on the PD-1 enrichment. The CD80 high Raji, which express ~3.5-fold higher CD80 than PD-L1, dramatically decreases PD-L1:PD-1 interface enrichment ( Figure 2C ), PD-1 phosphorylation and SHP2 recruitment ( Figure 2D ). Taken together, these results demonstrate that CD80 sequesters PD-L1 in cis to block PD-L1:PD-1 signaling, explaining a prior finding that co-expression of CD80 on tumor cells overcomes PD-L1 mediated suppression of T cell activity (Haile et al., 2011) . Thus, in addition to its wellestablished function in triggering CD28 co-stimulation, CD80 upregulates T cell activity by neutralizing an inhibitory ligand in cis.
PD-L1:CD80 cis-complex preserves the ability of CD80 to bind CD28
In the reciprocal experiment, we asked whether PD-L1:CD80 cis-interaction inhibits CD80:CD28 interaction. First, in a CD86 negative background, CD28-Fc stained CD80+PD-L1-Raji cells in a dose dependent manner ( Figure 3A, red) . Unexpectedly, co-expression of PD-L1 (5.9-fold higher than CD80, see Figure S4 for quantitation of expression levels) had no effect on the CD28-Fc binding at all concentrations tested ( Figure 3A , blue), indicating that PD-L1 does not affect CD80:CD28 interaction.
Consistent with this finding, in a T cell-SLB system in which CD80:CD28 trans-interaction is manifested by CD28 microclusters, addition of PD-L1 (three-fold excess to CD80) did not inhibit CD28 microcluster formation ( Figure 3B) . Furthermore, in the Raji-Jurkat coculture assay, Raji (CD80+/CD86+/PD-L1-) and Raji (CD80+/CD86+/PD-L1+) cells led to indistinguishable degrees of CD28 and CD80 interfacial enrichment and CD28 phosphorylation (measured by co-immunoprecipitated p85) (Figure 3C, D) . Importantly, PD-L1 was also enriched to the Raji-Jurkat interface in a CD80-dependent manner, suggesting that PD-L1, CD80, and CD28 form a tripartite complex that triggers CD28 signaling. Finally, knocking out CD80 from Raji significantly decreased the interfacial enrichment of both PD-L1 and CD28 ( Figure 3C , bottom), as well as CD28-mediated p85 recruitment ( Figure 3D ). The residual p85 recruitment under this condition was due to CD86:CD28 interaction, because knocking out both CD80 and CD86 abolished this signal ( Figure 3E) . Collectively, these data demonstrate that PD-L1 does not affect CD80:CD28 trans-interaction and PD-L1:CD80 heterodimer is fully capable of activating CD28.
PD-L1 protects CD80 from CTLA4 mediated trans-endocytosis
We next asked if the PD-L1:CD80 cis-interaction impacts the CD80:CTLA4 interaction.
At a CD86 negative background, CTLA4-Fc stained CD80+PD-L1-Raji cells in a dose dependent manner (Figure 4A, red) . Co-expression of PD-L1 (5.9-fold excess to CD80, see Figure S4 for quantitation of expression levels) substantially decreased CD80-mediated CTLA4-Fc staining ( Figure 4A , blue), resulting in a 4.7-fold higher apparent dissociation constant (KD, 0.52 ± 0.16 μg/ml versus 0.11 ± 0.03 μg/ml). This result demonstrates that PD-L1:CD80 cis-interaction inhibits CD80:CTLA4 interaction, contrasting to the lack of effect on CD80:CD28 interaction. Our attempt to verify this finding in the T cell-SLB assay by probing CTLA4 plasma membrane microclusters was precluded by the intracellular localization of CTLA4, consistent with previous reports (Alegre et al., 1996; Linsley et al., 1996; Qureshi et al., 2012; Valk et al., 2008 ). Indeed, a major function of CTLA4 is to bind and trans-endocytose CD80 and CD86 (Hou et al., 2015) , causing their depletion from APCs and weaker CD28 activation. Based on our finding that PD-L1 inhibits CD80:CTLA4 interaction, we predicted that PD-L1 protects CD80 from CTLA4-mediated depletion. To test this, we established a CTLA4-mediated trans-endocytosis assay: CTLA4-mGFP transduced Jurkat, but not wild-type Jurkat, decreased CD80 levels on Raji cells upon 30 minutes of cell contact ( Figure 4B ), indicating that CTLA4 trans-endocytosed CD80 from Raji APCs. Remarkably, coexpression of PD-L1 on Raji APCs significantly restored the CD80 level ( Figure 4B ). Thus, PD-L1 protects CD80 from CTLA4-mediated depletion.
PD-L1 blockade antibodies downregulate CD80 on APCs in a CTLA4 dependent manner
A key prediction from our finding is that the FDA-approved PD-L1 blockade antibody atezolizumab, which blocks PD-L1:CD80 cis-interaction ( Figure 1D ), would deplete CD80 from APCs in a CTLA4-dependent manner. Consistent with notion, we found that atezolizumab treatment decreases CD80 on Raji APCs, and strikingly, this effect was substantially reversed by the CTLA4 blockade antibody ipilimumab ( Figure 4C ). We further test this model in a coculture system containing primary mouse dendritic cells (DC) and regulatory T cells (Treg), a type of suppressive T cells that downregulate CD80 and CD86 in vivo through CTLA4-mediated trans-endocytosis (Hou et al., 2015; Schmidt et al., 2009) 
DISCUSSION
More than a decade after the first documentation of PD-L1:CD80 interaction (Butte et al., 2007) , the biochemical and functional consequence of this interaction is still a mystery.
The ability of CD80-expressing cells to bind PD-L1 coated surface led Butte et al. and the field to assume a trans-interaction model. By contrast, Freeman and colleagues recently proposed a cis-nature of this interaction (Chaudhri et al., 2018) . In addition, the number of molecules involved (PD-1, CTLA-4, CD28, PD-L1, CD80) and the expression of PD-L1 and CD80 on both APCs and T cells has made it extremely challenging to determine the roles of PD-L1:CD80 interaction.
Using in vitro and cellular reconstitution assays, we demonstrate that PD-L1 and CD80 bind in cis but not in trans, thereby substantially simplifying the PD-L1:CD80:PD-1:CD28:CTLA4 network. We then discover that PD-L1:CD80 cis-interaction on APCs simultaneously represses two major immune checkpoints: PD-L1:PD-1 and CD80:CTLA4 pathways, while leaving CD80:CD28 interaction unaffected. Figure 6 ). It is likely that CD80:CTLA4 interface but not CD80:CD28 interface overlaps with CD80:PD-L1 interface. Despite the lack of a crystal structure of CD80:CD28 complex, crosslinking and mass spectrometry analyses indicate that CD80:CD28 interface is structurally distinct from CD80:CTLA4 interface, with the prior driven by electrostatic interactions and the latter driven by hydrophobic interactions (Sorensen et al., 2004) .
Our results uncover an unexpected role of PD-L1 in repressing the CTLA4 pathway.
Independent to its well-established role in triggering PD-1 in trans, PD-L1 can block CD80:CTLA4 interaction through binding to CD80 in cis. Importantly, this allows PD-L1 to protect CD80 from CTLA4-mediated trans-endocytosis, thereby sustaining CD80 levels on APCs. From a different perspective, PD-L1 steers CD80 from CTLA4 to CD28, while free CD80 strongly prefers CTLA4 over CD28, the PD-L1 bound CD80 interacts with CD28 only (Figure 6 ). Though atezolizumab is best known to block PD-L1:PD-1 interaction, we show that it also block PD-L1:CD80 cis-interaction ( Figure 1D ).
Consequently, atezolizumab frees up CD80 for CTLA4-mediated trans-endocytosis, causing CD80 downregulation on APCs. Thus, our study reveals two opposing effects of atezolizumab on T cell signaling: first, atezolizumab blocks PD-L1:PD-1 interaction to stimulate T cell activation; second, by dissolving PD-L1:CD80 heterodimers, atezolizumab switches CD80 from a CD28 ligand to a CTLA4 ligand, thereby inhibiting T cell activation. We speculate that the net outcome of atezolizumab depends on the relative expression levels of PD-1 and CTLA4. Our model predicts that as PD-1 levels increase on T cells, PD-L1 would switch from a positive regulator (CD80 protecting) to a negative regulator (PD-1 triggering). Importantly, despite the general assumption that anti-PD-1 and anti-PD-L1 therapies have identical clinical responses, we show that anti-PD-L1 but not anti-PD-1 depletes CD80 on APCs (Figure 5) . Indeed, clinical trials have revealed that anti-PD-1 have a significantly higher overall response rate than anti-PD-L1 Passiglia et al., 2018) .
Data presented here provide a mechanistic rationale for co-blockade of PD-L1 and CTLA4 in cancer immunotherapy, a form of combination therapy currently under evaluation in clinical trials (Chae et al., 2018) . As reported in Figure 4D , CTLA4 blockade negates the CD80-depleting effect of PD-L1 blockade. Our finding also suggests that PD-L1 inhibitors that selectively block PD-L1:PD-1 interaction, but not PD-L1:CD80 interaction, might prove more effective than atezolizumab and other PD-L1:PD-1/PD-L1:CD80 dual blockers (e.g., durvalumab, avelumab) in immunotherapy.
The present study also elucidates that by sequestering PD-L1 in cis, CD80 on APCs functions as a rheostat for PD-L1:PD-1 signaling (Figure 6) , suggesting CD80 as a biomarker for PD-L1:PD-1 targeted immunotherapy. Currently, PD-L1 expressions on tumors and tumor infiltrating APCs are often used to predict patient response for PD-1 targeted therapy (Kluger et al., 2017; Lin et al., 2018; Tang et al., 2018) . Despite a positive correlation between PD-L1 expression and patient response, many PD-L1 positive patients fail to respond to PD-1 or PD-L1 blockade antibodies. Our study suggests that patients with high CD80 expression on tumor infiltrating APCs would less likely respond to PD-L1 or PD-1 inhibitors even though they are PD-L1 positive, because CD80 would mask PD-L1 in cis to prevent PD-1 activation in the first place. It is also worth noting that CD80 can block at least some clones of PD-L1 staining antibodies, leading to a substantial underestimation of PD-L1 levels on CD80+ cells (Figure S1A) . Therefore, choosing the right clones of PD-L1 staining antibodies would be essential for reliably probing PD-L1 levels in tumor tissues. supplemented with 10% fetal bovine serum (Omega Scientific, catalog FB-02), 100 U/mL of Penicillin (GE Healthcare, catalog SV30010), and 100 µg/mL of Streptomycin (GE Healthcare, catalog SV30010)) at 37 °C/5% CO2. Jurkat T cells and Raji B cells were maintained in RPMI medium (corning, catalog 10-041-CM) supplemented with 10% fetal bovine serum, 100 U/mL of Penicillin, and 100 µg/mL of Streptomycin) at 37 °C/5% CO2.
METHODS
HEK293F cells were maintained in FreeStyle 293 Expression Medium (Thermo Fisher
Scientific, catalog 12338018) at 37 °C/8% CO2. OT-1 splenocytes were harvested from C57BL/6-Tg (TcraTcrb) 1100Mjb/J (OT-1) mice (Jackson Laboratory) and maintained in OT-1 culture medium (RPMI 1640 supplemented with 10% fetal bovine serum, 1 mM Sodium Pyruvate (Corning, 25-000-CI), 50 µM β-mecaptoethanol (Fisher Scientific, catalog ICN19024283), 100 U/mL of Penicillin, and 100 µg/mL of Streptomycin) at 37 °C/5% CO2.
Recombinant proteins
Recombinant His-tagged mouse and human PD-L1, PD-L2, CD80, CD86, and ICAM used in OT-1-SLB assay or LUVs-SLB adhesion assay were purchased from Sino Biological.
For FRET assay using LUVs, extracellular portion (ectodomain) of human PD-L1 (aa 19-239), human PD-L2 (aa 20-220), or human CD80 (aa 35-242) was expressed in HEK293F cells, as described previously (Murin et al., 2014) . The N terminus of each ectodomain was fused with the signal peptide of HIV envelope glycoprotein gp120 followed by a twinstrep tag (amino acids sequence:
WSHPQFEKGGGSGGGSGGSAWSHPQFEK) and a SNAP-tag. The C terminus of each extracellular segment was fused with a decahistidine (His) tag. For His-tag free CD80, the His-tag coding sequence was removed from the expression construct. All His-tagged proteins were purified from the cell culture medium using HisTrap Excel column (GE Healthcare, catalog 17371206) and eluted using buffer containing 50 mM HEPES-NaOH, pH 8.0, 150 mM NaCl, 0.5 M imidazole. His10-tag free CD80 ectodomain was purified with a StrepTrap HP column (GE Healthcare, catalog 28907547) in 100 mM Tris-HCl, 150
mM NaCl, 1 mM EDTA, pH 8.0 and eluted with the same buffer containing 2.5 mM desthiobiotin (Sigma-Aldrich, catalog D1411). The ectodomain of mouse MHC-I molecule H2-Kb was produced as a disulfide-stabilized single chain trimer with a covalently linked ovalbumin (OVA) peptide SIINFEKL (Mitaksov et al., 2007) , and a C-terminal His-tag, using the Bac-to-Bac baculovirus expression system, as previously described (Hui et al., 2017) . All affinity-purified proteins were size-exclusion-purified using a Superdex 200
Increase 10/300 GL column (GE Healthcare, catalog 28990944) in HEPES buffered saline (50 mM HEPES-NaOH, pH 7.5, 150 mM NaCl, 10% glycerol). Gel filtered proteins were labeled with either SNAP-Cell 505 (NEB, catalog S9103S) or SNAP-Cell TMR (NEB, catalog S9105S) following manufacturer's instructions. Free dyes were then removed using Zeba Spin Desalting Columns (Thermo Fisher Scientific, catalog P187769). All proteins were quantified by SDS-PAGE and Coomassie blue staining, using bovine serum albumin (BSA, Thermo Scientific, catalog 23209) as a standard.
Cell lines generation
To nm. Donor images before and after acceptor photobleaching were acquired for FRET analysis using ImageJ (Fiji) with the AccPbFRET plugin, as described (Roszik et al., 2008) .
FRET assay with protein reconstituted LUVs
Synthetic 1,2-dioleyl-sn-glycero-3-phosphocholine (POPC, catalog 850457C) and 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl) iminodiacetic acid) succinyl] (nickel salt, DGS-NTA-Ni, catalog 790404C) were purchased from Avanti Polar Lipids. LUVs composing of 80% POPC and 20% DGS-NTA-Ni were generated by the extrusion method, as described (Hui and Vale, 2014) . Briefly, desired lipids were mixed in chloroform, dried 
LUVs-SLB adhesion assay
To form SLB, a glass bottom 96-well plate was incubated with 5% Hellmanex III (Hëlma Analytics, catalog Z805939) overnight on a 50 °C heat pad, thoroughly rinsed with ddH2O
and sealed with Nunc sealing tape (Thermo Fisher Scientific, catalog 232698). The desired wells were washed twice with 5 M NaOH (30 minutes each), and three times with channel in the TIRF field was calculated using the ImageJ software.
OT-1-SLB microscopy assay
OT-1 primary T cells were retrovirally transduced with either mouse PD-1-mCherry or mouse CD28-mGFP. Retroviruses were produced as described previously (Hui et al., 2017) . Freshly harvested OT-1 splenocytes were stimulated with 10 nM SIINFEKL peptide (Anaspec, catalog AS-60193-1) in OT-1 culture medium supplemented with 100 U/ml mouse recombinant IL-2 (Thermo Fisher Scientific, catalog 14802164) in a 37 °C/5% CO2 incubator. 36 hours later, cells were resuspended in retrovirus supernatants containing 8 µg/ml Lipofectamine and 100 U/ml mouse recombinant IL-2, spin-infected at 35 °C, 1000 × g for 120 minutes, and incubated at 37 °C/5% CO2 overnight. The virus supernatant was replaced with fresh OT-1 culture medium supplemented with 10 nM SIINFEKL peptide and 100 U/ml mouse recombinant IL-2 the second day and cells incubated for another 48-96 hours before microscopy. For TIRF microscopy, the 96-well plate was treated with SUVs to form SLB as described above. For Figure 2B 
Quantification of PD-L1 and CD80 expression
For flow cytometry based quantification, PD-L1 and CD80 were stained by anti-PD-L1 PE (eBioscience, catalog 14-5983-82) and anti-CD80 PE (Biolegend, catalog 305208) and their expression levels were quantified using the QUANTUM™ R-PE MESF kit (Bangs Laboratories Inc, catalog 827), following manufacturer's instructions. For western blotbased quantification, total cell lysate was applied for SDS-PAGE and detected by anti-PD-L1 PE (eBioscience, catalog 14-5983-82) and anti-CD80 (Novus Biologicals, NBP2-25255). The latter was further detected by using DyLight488 anti-mouse IgG (Biolegend, catalog 405310). Molecular densities were calculated assuming the following diameters:13 μm for Raji B cells (Hui et al., 2017) and 12.5 μm for DCs (Dumortier et al., 2005) .
Flow cytometry analysis of human monocyte-derived DCs
Human peripheral blood CD14+ monocytes were isolated from normal human peripheral blood (iXCells, catalog 10HU-008), and cultured in RPMI medium supplemented with 50 ng/ml of GM-CSF and 50 ng/ml of IL-4 in 37 °C/5% CO2. After five-day incubation, when the majority of monocytes were differentiated to immature 
Trans-endocytosis assay
For analyzing CD80 trans-endocytosis, CTLA4-mGFP expressing Jurkat or wild-type Jurkat cells were co-cultured with either PD-L1-mCherry expressing Raji or wild-type Raji.
Briefly, 0.4 million SEE-loaded Raji B cells and 0.4 million Jurkat T cells were mixed and co-pelleted by centrifugation at 290× g for one minute, and incubated at 37°C/5% CO2 for 30 minutes. After incubation, cells were resuspended and stained with anti-CD80 APC, anti-CD3 PE (Biolegend, 317308), and anti-CD20 PE/Cy7 (Biolegend, catalog 302311)
for flow cytometry with a BD LSRFortessa cell analyzer. CD3 and CD20 were used to gate Raji cells out from cell mixture. CD80 expression level was then analyzed on Raji.
For blockade treatment in Figure 4C , both SEE-loaded Raji and Jurkat were treated with 2 μg of either atezolizumab (Selleckchem, catalog A2004) or ipilimumab (Selleckchem, catalog A2001) per million cells for 15 minutes prior to mixing, and blockade antibodies were kept in the coculture until the staining step. For confocal microscopy, stained cells were plated on Poly-D-lysine treated glass bottom 96-well plate and images were acquired with an FV1000 confocal microscope in GFP and APC channels.
DCs-Treg cells co-culture Assay
Tcon cells and Treg cells were isolated using magnetic bead isolation system. In brief, total CD4+ T cells were first isolated from Foxp3 and/or anti-CTLA4 (50 µg/ml, Bio X Cell catalog BE0164) in RPMI 1640 supplemented with 10% fetal bovine serum, 50 µM β-mecaptoethanol, 100 U/mL Penicillin, and 100 µg/mL Streptomycin, 0.5 µg/ml Anti-CD3 mAb (Bio X Cell, catalog BE0001-2) and 1 µg/ml LPS (Enzo Life Sciences, catalog ALX-581-008-L002). After 16 hours, cells were first stained with Ghost Dye Red 780 (Tonbo Biosciences, catalog 13-0865-T100), followed by surface antibody staining for Ly5.1 (eBioscience, catalog 11-0453-82); Thy1.1 (eBioscience, catalog 12-0900-83); CD11c (eBioscience, catalog 45-0114-82); CD80 (Biolegend, catalog 104733); CD86 (eBioscience, catalog 17-0862-82); and PD-L1
(Biolegend, catalog 124315). An LSRFortessa analyzer (BD Biosciences) was used for data collection, and FlowJo software was used for data analysis. was used for data collection. FlowJo software was used for data analysis.
Anti-PD-
Quantification and statistical analysis
Unless otherwise indicated, data were reported as mean ± SEM, and number of replicates were indicated in figure legends. Curve fitting and normalization were performed in GraphPad Prism 5. Statistical significance was evaluated by two-tailed Student's t test (*, p < 0.05; **, p < 0.01; ***, p < 0.001) in GraphPad Prism 5. Data with p < 0.05 are considered statistically significant. Figure 2D , Figure 3D and Figure 3E . Z.H. assisted experiments in Figure 2B and 
